Wealthfront was founded in 2008, offers a range of exchange-traded funds (ETFs) managed by other companies, and has more than $50 billion in assets under management (AUM). When ma ...

CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

The CRSP U.S. Mid Cap Index comprises stocks that fall within about the 80th percentile of U.S. stock market capitalization.

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

Bullish option flow detected in Crispr Therapeutics (CRSP) with 3,734 calls trading, 1.3x expected, and implied vol increasing almost 4 points ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

Creating a well-diversified portfolio through individual stock selection requires extensive research, constant monitoring, ...

CRISPR Therapeutics' lone approved product has billion-dollar potential, while its pipeline also looks exciting. Amgen can make waves in the weight loss market, as well as others, thanks to a strong ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...